医学信息2025，Vol.38Issue(22)：32-38,7.DOI:10.3969/j.issn.1006-1959.2025.22.005
甲磺酸萘莫司他用于维持性血液透析抗凝的Meta分析
Meta-analysis of Nafamostat Mesilate for Anticoagulation in Maintenance Hemodialysis
摘要
Abstract
Objective To evaluate the efficacy and safety of nafamostat mesylate for anticoagulation in maintenance hemodialysis from the perspective of evidence-based medicine.Methods PubMed,CCTR,EMBASE,China National Knowledge Infrastructure(CNKI),VIP Database and WANFANG DATA databases were searched online for randomized controlled trials(RCTs)of nafamostat mesylate for anticoagulation in maintenance hemodialysis.Two independent researchers screened the literature,extracted the data and cross-checked.The quality of the literature was evaluated using the bias risk evaluation criteria provided by the Cochrane Collaboration;the PRISMA flow chart of RevMan5.4 software was used to show the screening process,and Meta-analysis was performed on the studies involved in the literature.Nafamostat mesylate in vitro anticoagulation was used as the experimental group,and other anticoagulation methods were used as the control group.The anticoagulation efficiency,filter life,activated partial thromboplastin time(APTT),activated clotting time(ACT),urea clearance index(Kt/V),platelet count(PLT)and adverse reactions were compared between the two groups.Results A total of 7 RCT studies involving 638 subjects were included.The quality of the included literature was general,the blind method was generally missing,and there was no publication bias.Meta-analysis showed that there was no difference in the effective rate between the experimental group and the control group[MD=1.12,95%CI(0.99,1.26),P=0.07].The experimental group could prolong the venous ACT[MD=-14.50,95%CI(-19.24,-9.75),P＜0.000 01]and venous APTT(P＜0.05).However,there were no significant difference in filter life[MD=0.32,95%CI(-1.34,1.99),P=0.70],arterial APTT[MD=-3.45,95%CI(-8.53,1.63),P=0.18],peripheral venous APTT[MD=-2.65,95%CI(-10.62,5.32),P=0.51],arterial ACT[MD=-5.19,95%CI(-23.43,13.05),P=0.58],PLT[MD=15.99,95%CI(-8.84,40.82),P=0.21]between the two groups.The adverse reactions in the experimental group were less than those in the control group[MD=0.35,95%CI(0.22,0.55)],P＜0.000 01].Descriptive analysis showed that the experimental group could increase Kt/V(P＜0.05).Conclusion Nafamostat mesylate has good anticoagulant effect and high safety in maintenance hemodialysis.关键词
甲磺酸萘莫司他/血液透析/Meta分析/抗凝效果Key words
Nafamostat mesylate/Maintenance hemodialysis/Meta-analysis/Anticoagulant effect分类
医药卫生引用本文复制引用
廖健,朱焕..甲磺酸萘莫司他用于维持性血液透析抗凝的Meta分析[J].医学信息,2025,38(22):32-38,7.基金项目
1.成都中医药大学"杏林学者"学科人才提升计划(编号:YYZX2021143) （编号:YYZX2021143）
2.内江市科技计划项目-中医药专项项目(编号:内中医药办发[2022]16号) （编号:内中医药办发[2022]16号）
